Questions? Feedback? powered by Olark live chat software
  • CLOSE
close× Call Us 1300 552 003

HCC1806; Breast Carcinoma; Human (Homo sapiens) Item ID: ATCCRL2335

Permits and Restrictions

View Permits View Restrictions
Organism Homo sapiens, human
Tissue mammary gland; breast
Cell Type Epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent, The line grows as attached medium-sized epithelial cells without floating cells.
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease TNM stage IIB, grade 2, primary acantholytic squamous cell carcinoma
Age 60 years
Gender female
Ethnicity Black
Karyotype Number of cells examined = 59; Modal Chromosome Number = 75 with a range of 65 to 79; Polyploidy Rate = 22%
Derivation The HCC1806 breast cancer cell line was initiated on July 31, 1995, and took 10 months to establish.
Clinical Data 60 years Black female
Receptor Expression estrogen receptor, negative progesterone receptor, negative
Oncogene her2/neu -, p53 -
Genes Expressed Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Cellular Products Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Comments The tumor was classified as a TNM Stage IIB, grade 2, acantholytic squamous carcinoma with no lymph node metastasis.

There was no family history of breast cancer.

The cells are poorly differentiated.

The cells are negative for expression of Her2-neu and for expression of p53.

HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.

The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).

The cells are homozygous for deletions in the FHIT gene at 3p14.2.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C
Subculture Ratio: 1:2 to 1:4 Medium Renewal: Every 2 to 3 days. Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
Cryopreservation Culture medium, 95%; DMSO, 5%
Culture Conditions Temperature: 37°C
STR Profile D5S818: 13 D13S317: 11 D7S820: 10, 12 D16S539: 10 vWA: 16, 18 TH01: 8 Amelogenin: X TPOX: 8, 9 CSF1PO: 12
Name of Depositor AF Gazdar, AK Virmani
References

Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Contact Us

E: care@invitro.com.au
P: 1300 552 003